LY3962673 in KRAS G12D-Mutant Solid Tumors

Phase 1, open-label trial of LY3962673 in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 5 years, Number of Participants with Dose Limiting Toxicities (DLT) at 28 days and 6 more. Started Sep 2024; status: active, not recruiting.